The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis
Abstract
A number of studies have examined the association between tumor protein 53 (TP53) mutations and the clinical outcome in patients with non-small-cell lung cancer (NSCLC), although these have yielded conflicting results. In the present study, electronic databases updated to September 2015 were searched to find relevant studies. A meta‑analysis was performed on the eligible studies, which quantitatively evaluated the association between the TP53 mutations and the survival of patients with NSCLC. Subgroup and sensitivity analyses were performed. A total of 19 studies that involved a total of 6,084 patients with NSCLC were included. When the TP53 mutation group (n=1,406) was compared with the wild-type group (lacking TP53 mutations; n=1,965), the wild‑type group was associated with a significantly higher overall survival rate [hazard ratio (HR), 1.26; 95% confidence interval (CI) 1.12‑1.41, P<0.0001]. Significant benefits of overall survival in the wild‑type group were found in the subgroup involving patients with NSCLC in the early stages, including the I/II phases (HR, 1.93, 95% CI, 1.17‑3.19, P=0.01; heterogeneity, I2=0.0%, P=0.976) and patients with adenocarcinoma (HR, 3.06; 95% CI, 1.66‑5.62, P<0.0001; heterogeneity: I2=0.0%, P=0.976). This meta‑analysis has indicated that TP53 gene alteration may be an indicator of a poor prognosis in patients with NSCLC. Furthermore, the results also suggested that the role of TP53 mutations may differ according to different pathological types and clinical stages. The presence of these mutations may define a subset of patients with NSCLC appropriate for investigational therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TP53 mutations appear in over 50% of patients with NSCLC 7-9, who have poorer clinical outcomes and shorter survival time than those without mutations 10-12.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Research works printed but not linked: 47
- Jemal, 2008, Cancer statistics, 2008, CA Cancer J Clin, 58, 71, 10.3322/CA.2007.0010 · DOI · Paper page
- Ihde, 1991, Non-small cell lung cancer. Part II: Treatment, Curr Probl Cancer, 15, 105
- Farjah, 2009, Multi-modality mediastinal staging for lung cancer among medicare beneficiaries, J Thorac Oncol, 4, 355, 10.1097/JTO.0b013e318197f4d9 · doi:10.1097/jto.0b013e318197f4d9
- Goldstein, 2011, Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies, Cancer Gene Ther, 18, 2, 10.1038/cgt.2010.63 · DOI · Paper page
- Singhal, 2005, Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review, Clin Cancer Res, 11, 3974, 10.1158/1078-0432.CCR-04-2661 · DOI · Paper page
- Toyooka, 2003, The TP53 gene, tobacco exposure, and lung cancer, Hum Mutat, 21, 229, 10.1002/humu.10177 · DOI · Paper page
- Greenblatt, 1994, Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res, 54, 4855
- Steels, 2001, Role of p53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis, Eur Respir J, 18, 705, 10.1183/09031936.01.00062201 · DOI · Paper page
- Tsao, 2007, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer, J Clin Oncol, 25, 5240, 10.1200/JCO.2007.12.6953 · DOI · Paper page
- Bodner, 1992, Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation, Oncogene, 7, 743
- Lohmann, 1993, Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives, Diagn Mol Pathol, 2, 36, 10.1097/00019606-199303000-00006 · DOI
- Harris, 1993, Clinical implications of the p53 tumor-suppressor gene, N Engl J Med, 329, 1318, 10.1056/NEJM199310283291807 · DOI · Paper page
- Mitsudomi, 2000, Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis, Clin Cancer Res, 6, 4055
- Huncharek, 2000, Prognostic significance of p53 mutations in non-small cell lung cancer: A meta-analysis of 829 cases from eight published studies, Cancer Lett, 153, 219, 10.1016/S0304-3835(00)00381-5 · DOI
- Kosaka, 2009, Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma, J Thorac Oncol, 4, 22, 10.1097/JTO.0b013e3181914111 · DOI · Paper page
- Fukuyama, 1997, K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer, Br J Cancer, 75, 1125, 10.1038/bjc.1997.194 · DOI
- Mitsudomi, 1993, Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer, J Natl Cancer Inst, 85, 2018, 10.1093/jnci/85.24.2018 · DOI · Paper page
- Tomizawa, 1999, Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma, Oncogene, 18, 1007, 10.1038/sj.onc.1202384 · DOI
- Lee, 2015, The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations, Mol Carcinog, 54, 93, 10.1002/mc.22077 · DOI
- Scoccianti, 2012, European Early Lung Cancer Consortium: Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort, Eur Respir J, 40, 177, 10.1183/09031936.00097311 · DOI
- Ma, 2014, Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer, Mol Oncol, 8, 555, 10.1016/j.molonc.2013.12.015 · DOI
- Chien, 2010, Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors, Ann Surg Oncol, 17, 1194, 10.1245/s10434-009-0853-2 · DOI
- Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 · DOI · Paper page
- Williamson, 2002, Aggregate data meta-analysis with time-to-event outcomes, Stat Med, 21, 3337, 10.1002/sim.1303 · DOI · Paper page
- Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 · DOI · Paper page
- Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
- Top, 1995, Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer, Int J Cancer, 64, 83, 10.1002/ijc.2910640203 · DOI
- Kashii, 1995, Evaluation of prognostic-significance of p53 gene alterations in patients with surgically resected lung-cancer, Int J Oncol, 6, 123
- Regina, 2009, Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN, Clin Chem, 55, 1834, 10.1373/clinchem.2009.123695 · DOI
- Huang, 1998, Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer, Int J Oncol, 12, 553
- Molina-Vila, 2014, Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer, Clin Cancer Res, 20, 4647, 10.1158/1078-0432.CCR-13-2391 · DOI · Paper page
- Vega, 1997, p53 Exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer, Br J Cancer, 76, 44, 10.1038/bjc.1997.334 · DOI
- Ahrendt, 2003, p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study, J Natl Cancer Inst, 95, 961, 10.1093/jnci/95.13.961 · DOI · Paper page
- Mitsudomi, 1995, p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival, Ann Oncol, 6, S9, 10.1093/annonc/6.suppl_3.S9 · doi:10.1093/annonc/6.suppl_3.s9
- Ohno, 1997, p53 status and prognosis in stage I–IIIa non-small cell lung cancer, Int J Oncol, 10, 521
- Ludovini, 2008, Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: A study of the perugia multidisciplinary team for thoracic oncology, J Thorac Oncol, 3, 365, 10.1097/JTO.0b013e318168c7d0 · DOI
- Horio, 1993, Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer, Cancer Res, 53, 1
- Schiller, 2001, Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy, J Clin Oncol, 19, 448, 10.1200/JCO.2001.19.2.448 · DOI · Paper page
- Tolbert, 1999, p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status, Mod Pathol, 12, 54
- Meinhold-Heerlein, 2001, Evaluation of methods to detect p53 mutations in ovarian cancer, Oncology, 60, 176, 10.1159/000055316 · DOI
- Fong, 1995, Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer, Cancer Res, 55, 4268
- Sozzi, 1992, Deletions of 17p and p53 mutations in preneoplastic lesions of the lung, Cancer Res, 52, 6079
- Ahrendt, 2003, p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study, J Natl Cancer Inst, 95, 961, 10.1093/jnci/95.13.961 · DOI · Paper page
- Poeta, 2007, TP53 mutations and survival in squamous-cell carcinoma of the head and neck, N Engl J Med, 357, 2552, 10.1056/NEJMoa073770 · DOI · Paper page
- Chiba, 1990, Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group, Oncogene, 5, 1603
- Soussi, 2001, Assessing TP53 status in human tumours to evaluate clinical outcome, Nat Rev Cancer, 1, 233, 10.1038/35106009 · DOI · Paper page
- Bria, 2015, Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma, Oncotarget, 6, 12783, 10.18632/oncotarget.3727 · DOI
Cited by
Lee, T.-Y., Huang, K.-Y., Chuang, C.-H., Lee, C.-Y., & Chang, T.-H. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107277 · Cited by 95
Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC
Cooper, A. J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y. P., Piotrowska, Z., Dagogo-Jack, I., Sequist, L. V., Gainor, J. F., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100390 · Cited by 14
Bian, S., Bian, H., Koyama, H., Kompaniiets, D., Tse, W., Shah, M. V., Al-Kali, A., Miron, A., Liu, B., & Liu, S. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131687
Self-citation
Metadata
- Authors
- Gu, J., Zhou, Y., Huang, L., Ou, W., Wu, J., Li, S., Xu, J., Feng, J., & Liu, B.
- Venue
- Molecular and Clinical Oncology
- Publisher
- Spandidos Publications
- Published
- 2016-10-21
- Volume
- 5
- Issue
- 6
- Pages
- 705-713
- ISSN
- 2049-9450
- 2049-9469
- Cited by
- 89
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis. https://app.cochat.ai/papers/10.3892/mco.2016.1057
- The paper
- Gu, J., Zhou, Y., Huang, L., Ou, W., Wu, J., Li, S., Xu, J., Feng, J., & Liu, B. (2016). TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis. Molecular and Clinical Oncology. https://doi.org/10.3892/mco.2016.1057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.